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antagonist, SB209670, evaluated in our study [1], phar-an effect mediated through the ETA receptor [3]. The
macokinetic data confirmed that mean immunoreactiveobservation that contrast nephropathy was exacerbated
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abandoning the development of ET receptor antagonists
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